バイオイメージング試薬市場調査レポート、規模とシェア、成長機会、およびトレンド洞察分析―テクノロジー別、クラス別、モダリティ別、アプリケーション別、エンドユーザー別、によるおよび地域別―世界予測2025―2037 年

バイオイメージング試薬市場分析

Bioimaging reagents are widely utilized in magnetic resonance imaging (MRI) and other imaging diagnostic tools across various healthcare and pharmaceutical industries. Bioimaging reagents are a vital component of medical imaging as they help visualize body organs at molecular, cellular, and tissue levels during ultrasound, X-ray, CT scan, and MRI. Hence, the prevalence of chronic diseases is rising across the globe, which is expected to drive the demand for bioimaging reagents. Our bioimaging reagents market research experts have found that over 150 million patients undergo MRI scans annually across the globe. Additionally, around 10 million patients undergo MRI scans. Moreover, these reagents are utilized in the medical industry across the globe for diagnosing and monitoring diseases, and developing new drugs. The growing demand for medical imaging diagnostics, incorporation of advanced technologies in molecular imaging, and the prevalence of neurological, autoimmune, and respiratory diseases are also driving the growth of the bioimaging reagents market in countries such as Japan, India, and China. According to our insights into bioimaging reagent market trends, approximately 17% of men aged 40 and above in Japan suffer from COPD, increasing the demand for medical imaging across the country.

According to our analysis of the bioimaging reagents market, the following market trends and factors are predicted to contribute as core drivers of market growth:

• Increasing utilization of nuclear imaging reagents – The increasing use of radiopharmaceuticals for the diagnosis of various diseases is expected to boost the demand for nuclear imaging reagents across the globe. Advancements in imaging technologies and increasing adoption of molecular imaging techniques are also fueling the growth of the bioimaging reagents market. Bioimaging reagents play a vital role in diagnostic procedures by enhancing the visibility of specific tissues and organs during imaging examinations. Nuclear imaging is widely utilized to study the functioning of organs and tissues and nuclear imaging reagents are very essential to this process. Hence, the increasing utilization of nuclear imaging reagents will benefit the growth of the bioimaging reagents market. As per our bioimaging market trend insights, over 20 million nuclear medicine procedures are performed annually in the US.
• Increasing popularity of multimodal imaging - The demand for multimodal or multiplex imaging is growing over single modality imaging due to several advantages that multimodal imaging offers such as improved visual acuity and more accurate images. Moreover, the introduction and assimilation of innovative technologies and tools, especially those using several imaging modalities, is garnering attention worldwide. Meanwhile, with PET-SPECT hybrid and PET-MRI imaging systems being widely used for diagnostic purposes, manufacturers are finding greater potential in the fields of research and drug development, focusing on multimodal methodologies.

How will the Bioimaging Reagents market benefit market players in Japan ?

Japan has contributed significantly to providing innovative medicines to patients, and domestic biopharmaceutical companies have helped improve health and drive economic growth. Bioimaging technologies and bioimaging reagents play a key role in drug discovery and development. However, it is imperative for Japanese manufacturing to prioritize innovation to address the unmet needs of Japanese patients and address future challenges. Our market research experts have found that cardiovascular disease is the second leading cause of death in Japan. These rising costs of treatment can be controlled by developing new drugs, reducing overall medical costs, optimizing clinical pathways, and strengthening community healthcare nationwide. To address these issues, Novartis has established a strategic public-private partnership in Japan, which is estimated to benefit the growth of the bioimaging reagents market across Japan.

On the other hand, pharmaceutical companies play a vital role in contributing to improving the health and medical care of the people of our country. In 2024, Japan's Minister of Health, Labor and Welfare, Takemi, announced that the government should take the lead in building a drug discovery platform for a new Japan. This will lead to an increase in the requirement for bioimaging technology, which is likely to increase the demand for bioimaging reagents across the country during the forecast period. Furthermore, the strengthening R&D environment and biotechnology startups in Japan, as well as improving regulatory requirements, are also expected to drive the growth of the bioimaging reagents market.

Market Issues

The risk of radiation exposure and the time taken for regulatory approval are believed to be some of the major restraints for the growth of the bioimaging reagents market during the forecast period.

競争力ランドスケープ

バイオイメージング試薬業界の概要と競争のランドスケープ

SDKI Inc. の調査者によると、バイオイメージング試薬市場は、大企業と中小規模の組織といったさまざまな規模の企業間の市場競争により細分化されています。市場関係者は、製品や技術の発売、戦略的パートナーシップ、コラボレーション、買収、拡張など、あらゆる機会を利用して市場での競争優位性を獲得しています。

世界のバイオイメージング試薬市場の成長に重要な役割を果たす主要な主要企業には、Bayer AG、Thermo Fisher Scientific, Inc.、GE Healthcare Technologies Inc.、PerkinElmer AES、Siemens Healthineers AGなどが含まれます。 さらに、日本のバイオイメージング試薬市場のトップ5プレーヤーは、Sumitomo Corporation、Shimadzu Corporation、 FUJIFILM Corporation、 TAKARA Bio Inc.、 およびGORYA Chemical Incなどです。 この調査には、世界のバイオイメージング試薬市場分析レポートにおける詳細な競合分析、企業概要、最近の動向、およびこれらの主要企業の主要な市場戦略が含まれています。

バイオイメージング試薬市場ニュース

• 2024 年 1 月、Biocare Medical と Molecular Instruments は協力して、ONCORE Pro X および HCR RNA-ISH アッセイを通じて自動バイオイメージングに革命をもたらしました。
• 2023 年12月、Fujirebio およびSysmexは、免疫測定法分野における試薬原料の相互供給に関する協定を締結しました。